NDC 0310-4535

IMJUDO

Tremelimumab

IMJUDO is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Tremelimumab.

• Product ID: 0310-4535_6690679c-be2f-4588-a2e4-89fff74dd6be
• NDC: 0310-4535
• Product Type: Human Prescription Drug
• Proprietary Name: IMJUDO
• Generic Name: Tremelimumab
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2022-10-21
• Marketing Category: BLA /
• Application Number: BLA761289
• Labeler Name: AstraZeneca Pharmaceuticals LP
• Substance Name: TREMELIMUMAB
• Active Ingredient Strength: 300 mg/15mL
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0310-4535-30

1 VIAL in 1 CARTON (0310-4535-30) > 15 mL in 1 VIAL

• Marketing Start Date: 2022-10-21
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "IMJUDO" or generic name "Tremelimumab"

NDC	Brand Name	Generic Name
0310-4505	IMJUDO	tremelimumab
0310-4535	IMJUDO	tremelimumab